Rucaparib瑞卡帕布醋酸盐,773059-23-7

价格询价

品牌MedChemExpress(MCE)
产地美国
货号HY-10617D
更新日期2025年12月05日

MedChemExpress LLC

品牌商

14 年钻石会员

Rucaparib acetate

CAS No. : 773059-23-7

MCE 国际站：Rucaparib acetate

产品活性：Rucaparib (AG014699) acetate 是一种口服有效的 PARP 蛋白 (PARP-1, PARP-2 and PARP-3) 抑制剂，对 PARP-1 的 K_i 为 1.4 nM。Rucaparib acetate 是六磷酸己糖脱氢酶 (H6PD) 抑制剂。Rucaparib acetate 具有用于去势抵抗性前列腺癌 (CRPC) 研究的潜力。

研究领域：Cell Cycle/DNA Damage | Epigenetics

作用靶点：PARP

In Vitro: Rucaparib (AG014699) acetate is a possible N-demethylation metabolite of AG14644.
Rucaparib (0.1, 1, 10, 100 μM; 24 hours) acetate is cytotoxic and has the LC₅₀ being 5 μM in Capan-1 (BRCA2 mutant) cells and only 100 nM in MX-1 (BRCA1 mutant) cells.
The radio-sensitization by Rucaparib acetate is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib acetate can target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions.
Rucaparib acetate inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells.

In Vivo: Rucaparib (AG014699) acetate and AG14584 significantly increase Temozolomide toxicity. Rucaparib (1 mg/kg) acetate significantly increases Temozolomide-induced body weight loss. Rucaparib (0.1 mg/kg) acetate esults in a 50% increase in the temozolomide-induced tumor growth delay.
Rucaparib (10 mg/kg for i.p. or 50, 150 mg/kg for p.o.; daily for 5 days per week for 6 weeks) acetate significantly inhibits the growth of the tumor, and there is one complete tumor regression and two persistent partial regressions.
Rucaparib (150 mg/kg; p.o.; once per week for 6 weeks or three times per week for 6 weeks) acetate has greatest antitumor effect with three complete regressions.
Rucaparib acetate enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts.